Sector Update: Health Care Stocks Mixed in Afternoon Trading
Aptevo's Mipletamig Achieves 90% Remission Rate in AML Trials, Surpassing Previous 66%; No Cytokine Release Syndrome In RAINIER Trial; Cohort 2 Enrollment Nearly Complete
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Aptevo to Participate in March Conferences
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Express News | Aptevo Therapeutics Inc Files for Mixed Shelf of up to $100 Mln - SEC Filing
10-K: FY2024 Annual Report
Aptevo Therapeutics 22024 EPS $(87.38), Cash Position $8.7M
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
Aptevo Therapeutics Showcases Promising Oncology Drug Pipeline
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
Roth MKM Initiates Aptevo Therapeutics(APVO.US) With Buy Rating, Announces Target Price $21
Aptevo Therapeutics (APVO) Receives a Buy From Roth MKM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Sector Update: Health Care Stocks Softer Thursday Afternoon
Aptevo Therapeutics Shares Slump After Warrant Exercised at a Discount
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Aptevo Therapeutics Shares Rally After Trial Results Show Complete Remission by Acute Myeloid Leukemia Patients
Aptevo Therapeutics Shares Resumed Trade